1668-19-5
Chemical Structure
Doxepin
- CAS No.: 1668-19-5
- Formula:C19H21NO
- Molecular Weight:279.38
IUPAC Name: (E)-3-(dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine
InChIKey: ODQWQRRAPPTVAG-GZTJUZNOSA-N
SMILES: CN(C)CC/C=C1C2=CC=CC=C2OCC3=CC=CC=C/13
Biological Activity: Doxepin is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to Desmethyldoxepin in vivo. Doxepin can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Doxepin | 99.66% | Doxepin is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to Desmethyldoxepin in vivo. Doxepin can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxepin-d3 | Doxepin-d3 is the deuterated-labeled Doxepin (HY-B0725A). Doxepin is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to Desmethyldoxepin in vivo. Doxepin can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bu J. Mechanism underlying the effects of doxepin on β-amyloid -induced memory impairment in rats. Iran J Basic Med Sci. 2017 Sep;20(9):1044-1049. [Content Brief]
- [2]. Pinder R M, et al. Doxepin Up-to-Date: A Review of its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Depression. Drugs, 1977, 13: 161-218.
- [3]. Chang GR, et al. Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice. Pharmaceuticals (Basel, Switzerland). 2021 Mar 16;14(3):267.
- [4]. Sun XY, et al. Characterization of the anticonvulsant activity of doxepin in various experimental seizure models in mice. Pharmacological reports : PR. 2009;61(2):245-51.
Keywords
